reMYND has appointed Floor Stam as chief executive officer and Johan Cardoen as chairman. The company is a spin-off from the University of Leuven, Belgium and is developing treatments for neurodegenerative diseases caused by neuronal dysfunction involving a small molecule programme of septin modulators. Dr Stam has experience in developing early-stage companies, co-founding oncology company Flamingo Therapeutics NV which achieved Phase 2 clinical stage within four years. A neurobiologist by training, she holds a PhD from Vrije Universiteit Amsterdam, the Netherlands. Mr Cardoen is on the board of several biotech companies and was previously managing director of VIB, a Belgian biotechnology institute, and CEO of CropDesign, overseeing its acquisition by BASF Plant Science in 2006.
reMYND announced the appointments on 3 September 2024.
Copyright 2024 Evernow Publishing Ltd.